menu
    • menu

    Company profile for Versanis Bio

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Versanis Bio is a clinical-stage biopharmaceutical company bringing transformational treatments to people living with cardiometabolic disease. The company’s lead asset, bimagrumab, is being advanced in a Phase 2b study as a novel treatment for obesity to help adults achieve and maintain both substantial fat loss and a healthy body composition, with additional indications to follow.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Versanis BioUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    31 Hudson Yards, 11th fl New York, NY
    Telephone
    Telephone
    (617) 315-4410
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.versanisbio.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/versanis-bio/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Aditum launches Celexor with autoimmune drug from Acelyrin partner Inmagene
    Aditum launches Celexor with autoimmune drug from Acelyrin partner Inmagene

    21 Sep 2023

    // Kyle LaHucik ENDPTS

    https://endpts.com/joe-jimenezs-fund-aditum-launches-its-10th-biotech-celexor-bio-with-autoimmune-drug-from-inmagene/

    Kyle LaHucik ENDPTS
    21 Sep 2023
    Share Share
    Lilly Completes Acquisition of Versanis Bio
    Lilly Completes Acquisition of Versanis Bio

    14 Aug 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lilly-completes-acquisition-of-versanis-bio-301899755.html

    PR NEWSWIRE
    14 Aug 2023
    Share Share
    Versanis Bio to Present New Data at American Diabetes Association 83rd Sessions
    Versanis Bio to Present New Data at American Diabetes Association 83rd Sessions

    23 Jun 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/versanis-bio-to-present-new-clinical-data-at-american-diabetes-association-83rd-scientific-sessions-301858731.html

    PR NEWSWIRE
    23 Jun 2023
    Share Share
    Versanis Announces Initiation of BELIEVE Global Phase 2b Study of Bimagrumab
    Versanis Announces Initiation of BELIEVE Global Phase 2b Study of Bimagrumab

    12 Jan 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/versanis-announces-initiation-of-the-believe-global-phase-2b-study-of-bimagrumab-as-a-novel-treatment-for-obesity-301720433.html

    PR NEWSWIRE
    12 Jan 2023
    Share Share
    Versanis Presents Preclinical Data Demonstrating the Potential of Bimagrumab
    Versanis Presents Preclinical Data Demonstrating the Potential of Bimagrumab

    02 Nov 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/versanis-presents-preclinical-data-demonstrating-the-potential-of-bimagrumab-as-a-novel-obesity-treatment-at-obesityweek-2022-301665807.html

    PRNEWSWIRE
    02 Nov 2022
    Share Share
    Versanis Bio Announces Leadership and Board Appointments
    Versanis Bio Announces Leadership and Board Appointments

    20 Jul 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/versanis-bio-announces-leadership-and-board-appointments-as-company-prepares-to-initiate-phase-2b-study-with-novel-approach-to-obesity-301589702.html

    PRNEWSWIRE
    20 Jul 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search